Clinical trials: Movement Abnormalities
Huntington's Disease
PINS Stimulator System for Deep Brain Stimulation in Huntington's Disease
Deep Brain Stimulation (DBS) of the Globus pallidus internus(GPi) is useful in the treatment of different forms of chorea, including Huntington's disease (HD).
- Trial name
- NCT02263430
- Testing
- Deep Brain Stimulation
- Volunteers
- 8 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Angelman Syndrome
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)
This is a phase I, multicenter, non-randomized, adaptive, open-label, multiple ascending, intra-participant, dose-escalation study with a long-term extension (LTE) part and an optional open-label extension (OOE) part.
- Trial name
- NCT04428281
- Testing
- RO7248824
- Where
- 12 sites in United States, Italy and 2 more
- Volunteers
- 74 people
- Sponsor
- Hoffmann-La Roche
Parkinson Disease
Spectroscopy in Parkinson Disease
The primary objective of the study is to determine the utility of blood plasma infrared spectroscopy (biospectroscopy) in distinguishing subjects with idiopathic Parkinson's disease from healthy controls.
- Trial name
- SPIN-PD (NCT01005030)
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Molecular Biometrics, Inc.
Parkinson Disease
Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions
It is an open-label, balanced, randomized, five-treatment, five-period, five-sequence, multiple oral dose, crossover comparative bioavailability study of different strengths of carbidopa/levodopa extended-release tablets with…
- Trial name
- NCT05128175
- Testing
- WD-1603 Carbidopa-Levodopa Extended-Release Tablets
- Where
- India
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Shanghai WD Pharmaceutical Co., Ltd.
Parkinson Disease
Opicapone Treatment Initiation Open-Label Study
This is an observational study to describe the treatment patterns and clinical outcomes observed with use of ONGENTYS as adjunctive treatment to levodopa/carbidopa in Parkinson's disease patients experiencing "off" episodes with…
- Trial name
- OPTI-ON (NCT04787965)
- Testing
- Opicapone
- Where
- 6 sites in United States
- Volunteers
- 239 people
- Sponsor
- Neurocrine Biosciences
Parkinson's Disease, Levodopa Induced Dyskinesias (LID)
Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.
This study was terminated early due to slow enrollment with 87 of 162 planned subjects enrolled. The purpose of this multi-center, randomized, double-blind, parallel-group, 16 week study is to compare the efficacy and safety of…
- Trial name
- ALLAY-LID-I (NCT02153645)
- Testing
- 240mg Amantadine HCl ER tablets, 320mg Amantadine HCl ER tablets
- Where
- 56 sites in United States, Canada and 3 more
- Volunteers
- 87 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Parkinson Disease
Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients.
This is a phase 2, double-blind, multi-center, placebo-controlled clinical study to evaluate the safety, tolerability, efficacy, and PK of FHL-301 in adult patients with early-stage PD.
- Trial name
- NCT05931484
- Testing
- Gemfibrozil
- Sponsor
- Forest Hills Lab
Parkinson's Disease
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa
The purpose of this study is to the effect of three single oral doses of nebicapone (50 mg, 100 mg and 200 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled release levodopa…
- Trial name
- NCT02774564
- Testing
- BIA 3-202, Sinemet®
- Where
- Portugal
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites
The purpose of this study is: To determine the rate and routes of excretion of BIA 3-202 and the mass balance in urine and faeces To determine the kinetics of total radioactivity in blood To determine the kinetics of total…
- Trial name
- NCT02772614
- Testing
- BIA 3-202 (200 mg)
- Where
- Switzerland
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Relative Bioavailability and Bioequivalence of Opicapone
the purpose assess the relative bioavailability and bioequivalence of two active pharmaceutical ingredient (API) sources of opicapone (OPC, Ongentys® and BIA 9-1067) following single 50 mg dose administration under fasting…
- Trial name
- NCT03820037
- Testing
- Ongentys, BIA 9-1067 (test)
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
FitMi PD Home Therapy for Parkinson's Disease
The investigators will run an at-home usability study of a newly developed home exercise device (FitMi PD) for individuals with Parkinson's disease.
- Trial name
- NCT05655377
- Testing
- FitMi PD
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Flint Rehabilitation Devices, LLC
Parkinson's Disease (PD)
A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease
The main goal of the study is to investigate how well the new drug SUL-238 works in Parkinson's Disease (PD). This is done by means of an MRS scan. An MRS scan is similar to a regular MRI scan.
- Trial name
- SHEPHERD (NCT07322887)
- Testing
- SUL-238 (1500 mg t.i.d.) film-coated tablets, SUL-238 (500 mg t.i.d.) film-coated tablets
- Where
- Netherlands
- Volunteers
- 45 people
- Sponsor
- GEN İlaç ve Sağlık Ürünleri A.Ş.
Parkinson's Disease
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease
The primary objective of this study is to evaluate the safety and tolerability of a range of single and 13 repeated doses of BIIB054, administered as intravenous (IV) infusion, in Japanese participants with Parkinson's disease…
- Trial name
- NCT03716570
- Testing
- BIIB054
- Where
- 9 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Biogen
Idiopathic Parkinson's Disease
Evaluating Safety, Tolerability, and Efficacy of Autologous MitoCell Transplantation in Subjects With Idiopathic Parkinson's Disease
Primary Objective: To assess the safety profile of autologous MitoCell administered to subjects with idiopathic Parkinson's disease (PD) Secondary Objective: To explore the efficacy and safety of MitoCell given as the recommended…
- Trial name
- NCT05094011
- Testing
- Aadipose-Derived Mesenchymal Stem Cells
- Volunteers
- 9 people
- Sponsor
- Taiwan Mitochondrion Applied Technology Co., Ltd.
Tourette Syndrome
The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Tourette Syndrome
The purpose of this clinical study is to verify the long term effectiveness and safety of a bilateral deep brain stimulation (DBS) produced by Beijing PINS Medical Co., Ltd.
- Trial name
- NCT02253498
- Testing
- deep brain stimulation (DBS)
- Volunteers
- 20 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Huntington Disease, Huntington's Dementia
Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study
OBJECTIVES: The primary study objective is to collect blood from participants with Huntington's Disease in order to validate a CE marked Cytosine, Adenine, Guanine (CAG) assay for use in future studies for Huntington's Disease.
- Conditions
- Huntington Disease, Huntington's Dementia, Huntington Disease, Late Onset, Huntington; Dementia (Etiology)
- Trial name
- SAN-09611 (NCT05773196)
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sanguine Biosciences
Parkinson's Disease
Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa
This study will evaluate the safety and efficacy of administration of AFQ056 in combination with L-dopa, in reducing the number of L-dopa related dyskinesias in Parkinson's disease patients.
- Trial name
- NCT00582673
- Testing
- AFQ056
- Where
- 5 sites in Germany
- Volunteers
- 31 people
- Sponsor
- Novartis
Cardiovascular Event, Parkinson Disease
Cardiovascular Events in Parkinson's Disease Patients
Cardiovascular (CV) disease is a common comorbidity of Parkinson's disease (PD). The background incidence rate of CV events in a levodopa-treated PD population was assessed to better understand these comorbidities in the PD…
- Trial name
- NCT01545856
- Testing
- levodopa
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Dyskinesias, Parkinson Disease
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
This study is to evaluate long-term safety, tolerability and efficacy for AFQ056 in patients who have completed an AFQ056A study in Parkinson's disease L-dopa induced dyskinesias (PD-LID).
- Conditions
- Dyskinesias, Parkinson Disease, Movement Disorders, Parkinsonian Disorders
- Trial name
- NCT01491932
- Testing
- AFQ056
- Where
- 32 sites in United States, Austria and 8 more
- Volunteers
- 129 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson's Disease
VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)
The objective of this study is to assess the safety of VY-AADC02 in participants with Parkinson's disease (PD) with motor fluctuations.
- Trial name
- NCT03562494
- Testing
- VY-AADC02
- Where
- 11 sites in United States
- Volunteers
- 14 people
- Sponsor
- Neurocrine Biosciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.